Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer.
+ 1 more risk
Flawless balance sheet with limited growth.
Share Price & News
How has Autolus Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 6A3A's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 6A3A underperformed the German Biotechs industry which returned 6.2% over the past year.
Return vs Market: 6A3A underperformed the German Market which returned 15% over the past year.
Price Volatility Vs. Market
How volatile is Autolus Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Autolus Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 6A3A's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 6A3A's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 6A3A is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: 6A3A is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 6A3A's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 6A3A is good value based on its PB Ratio (1.9x) compared to the DE Biotechs industry average (3.5x).
How is Autolus Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 6A3A is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 6A3A is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 6A3A is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 6A3A's revenue (73.7% per year) is forecast to grow faster than the German market (5% per year).
High Growth Revenue: 6A3A's revenue (73.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 6A3A is forecast to be unprofitable in 3 years.
How has Autolus Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 6A3A is currently unprofitable.
Growing Profit Margin: 6A3A is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 6A3A is unprofitable, and losses have increased over the past 5 years at a rate of -54.7% per year.
Accelerating Growth: Unable to compare 6A3A's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6A3A is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: 6A3A has a negative Return on Equity (-47.57%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Autolus Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: 6A3A's short term assets ($260.2M) exceed its short term liabilities ($20.6M).
Long Term Liabilities: 6A3A's short term assets ($260.2M) exceed its long term liabilities ($24.4M).
Debt to Equity History and Analysis
Debt Level: 6A3A is debt free.
Reducing Debt: 6A3A has not had any debt for past 5 years.
Inventory Level: 6A3A has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if 6A3A's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6A3A has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 6A3A has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of -51.5% each year.
What is Autolus Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate 6A3A's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 6A3A's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 6A3A's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 6A3A's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 6A3A's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Chris Itin (55yo)
Dr. Christian Martin Itin, also known as Chris, Ph.D., has been the Chief Executive Officer of Autolus Therapeutics Plc. and Autolus Limited since March 3, 2016. Dr. Itin has been Director of Autolus Holdi ...
CEO Compensation Analysis
Compensation vs Market: Chris's total compensation ($USD1.61M) is above average for companies of similar size in the German market ($USD801.26K).
Compensation vs Earnings: Insufficient data to compare Chris's compensation with company performance.
|Chairman & CEO||3.9yrs||US$1.24m||2.04% $11.0m|
|Founder||0yrs||no data||1.34% $7.2m|
|CFO & Senior VP||1.7yrs||no data||no data|
|Senior VP & COO||3.3yrs||no data||0.21% $1.2m|
|Senior VP||2.6yrs||US$372.20k||0.24% $1.3m|
|Senior Vice President of Translational Sciences||2.6yrs||no data||no data|
|Senior VP & Chief Medical Officer||3.9yrs||no data||0.087% $468.5k|
|Senior Vice President of Regulatory Affairs & Quality||1.3yrs||no data||no data|
|Vice President of Corporate Affairs & Communications||0yrs||no data||no data|
|Senior VP & Head of Product Delivery||0.3yrs||no data||no data|
Experienced Management: 6A3A's management team is considered experienced (2.6 years average tenure).
|Chairman & CEO||3.9yrs||US$1.24m||2.04% $11.0m|
|Founder||0yrs||no data||1.34% $7.2m|
|Non-Executive Director||1.7yrs||US$77.70k||no data|
|Non-Executive Director||1.7yrs||US$100.50k||0.26% $1.4m|
|Non-Executive Director||1.7yrs||US$22.10k||no data|
|Non-Executive Director||1.7yrs||US$25.10k||no data|
|Non-Executive Director||1.7yrs||US$44.00k||0.14% $758.3k|
|Non-Executive Director||1.7yrs||US$266.10k||no data|
Experienced Board: 6A3A's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 48.6%.
Autolus Therapeutics plc's company bio, employee growth, exchange listings and data sources
- Name: Autolus Therapeutics plc
- Ticker: 6A3A
- Exchange: DB
- Founded: 2014
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$583.958m
- Listing Market Cap: US$538.584m
- Shares outstanding: 52.23m
- Website: https://www.autolus.com
Number of Employees
- Autolus Therapeutics plc
- Forest House
- 58 Wood Lane
- Greater London
- W12 7RZ
- United Kingdom
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|AUTL||NasdaqGS (Nasdaq Global Select)||Yes||SPON ADS EA REP 1 ORD SHS||US||USD||Jun 2018|
|6A3A||DB (Deutsche Boerse AG)||Yes||SPON ADS EA REP 1 ORD SHS||DE||EUR||Jun 2018|
Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 for the treatment of multiple myeloma; AUTO4 and AUTO 5 for T cell lymphoma; and AUTO6 and AUTO7 to treat solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/16 22:43|
|End of Day Share Price||2020/02/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.